C07K 14/1808
Alphaviruses or group a arboviruses
Official title: {Alphaviruses or Group A arboviruses, e.g. sindbis, VEE, EEE, WEE, semliki forest virus (rubella virus C07K14/19)}
C07K14/1808 (Alphaviruses or group a arboviruses) appears on 9 US grants and 17 published applications in this corpus.
Search patents in C07K- Granted patents
- 9
- Published applications
- 17
- Assignees
- 7
- Inventors
- 28
- Latest grant
- 19 Aug 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2013 | 0 | 1 |
| 2014 | 0 | 1 |
| 2015 | 0 | 0 |
| 2016 | 2 | 1 |
| 2017 | 0 | 0 |
| 2018 | 0 | 0 |
| 2019 | 0 | 1 |
| 2020 | 0 | 0 |
| 2021 | 0 | 4 |
| 2022 | 1 | 0 |
| 2023 | 2 | 3 |
| 2024 | 1 | 2 |
| 2025 | 3 | 2 |
| 2026 | 0 | 2 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Compositions and methods for inducing immune responses19 Aug 2025US 12,390,524 B2Arcturus Therapeutics, Inc.
- Alphavirus replicon encoding chimeric SARS-CoV-2 receptor binding domains22 Apr 2025US 12,280,102 B2VLP Therapeutics, LLC
- Coronavirus vaccine compositions and methods11 Feb 2025US 12,220,455 B2Arcturus Therapeutics, Inc.
- Multiplexed analysis of neuron projections by sequencing9 Jul 2024US 12,031,127 B2Cold Spring Harbor Laboratory
- Compositions and methods for inducing immune responses19 Sep 2023US 11,759,515 B2Arcturus Therapeutics, Inc.
- Modified madariaga viruses, self-replicating rna constructs, and uses thereof30 Jul 2026US 2026/0218170 A1Replicate Bioscience, Inc.
- Compositions and methods for inducing immune responses12 Mar 2026US 2026/0069677 A1Arcturus Therapeutics, Inc.
- Alphavirus replicon encoding chimeric sars-cov-2 receptor binding domains17 Jul 2025US 2025/0228931 A1VLP Therapeutics, LLC
- Coronavirus vaccine compositions and methods22 May 2025US 2025/0161434 A1Arcturus Therapeutics, Inc.
- Coronavirus vaccine compositions and methods11 Apr 2024US 2024/0115691 A1Arcturus Therapeutics, Inc.
Most cited
By later US patents
- Virus like particle composition22US 9,249,191 B2VLP Therapeutics, LLC · 2016
- Coronavirus vaccine compositions and methods4US 11,744,887 B2Arcturus Therapeutics, Inc. · 2023
- Coronavirus vaccine compositions and methods2US 12,220,455 B2Arcturus Therapeutics, Inc. · 2025
- Methods and compositions for pseudoinfectious alphaviruses2US 9,402,890 B2The UAB Research Foundation · 2016
- Compositions and methods for inducing immune responses1US 11,759,515 B2Arcturus Therapeutics, Inc. · 2023